Abstract
Pterygium is a common ocular lesion whose exact etiology is a point of contention. Chronic inflammation and angiogenesis are two major proposed mechanisms of the disease in the current literature. The objective of this study is to examine these two mechanisms in a very well-designed setting. In a case-control study, 24 tissue specimens from the patients with primary moderate pterygium (cases) and 15 specimens excised from the nasal bulbar region in healthy counterparts (controls) were compared in terms of the count of mast cells (inflammation), as well as the status of Cd31/vascular Endothelial Growth Factor (VEGF) expression (angiogenesis) in Tabriz Nikookari and Sina Teaching Hospitals. The case (mean age: 58.08 +/- 10.03 years, 84% males) and control (Mean age: 62.33 +/- 9.19 years, 80% males) groups were age-and sex-matched (p = 0.19, 0.75, respectively). The mean mast cell count was significantly higher in the case group (27.72 +/- 15.19 versus 12.00 +/- 7.09 cells mm(-2), p = 0.001). The study of immunoreactivity revealed that the positive expression (moderate-severe) of CD31 was significantly more frequent in the case group (88 versus 26.7%; p<0.001; Odds ratio = 20, 95% confidence interval 3.85-100). There was also higher rate of VEGF-positive (moderate-severe) cells in the group with pterygium (88 versus 20%; p<0.001; Odds ratio= 33.3, 95% confidence interval 5.00-100). This study indicates that both inflammation and angiogenesis play pivotal role, in parallel, in pathogenesis of pterygium.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.